Application of thermoelectric field therapy in chronic prostatitis/chronic pelvic pain syndrome

doi:10.3877/cma.j.issn.1674-3253.2020.01.014

Abstract

Abstract:

Objective

To evaluate the improvement of symptoms in patients with chronic prostatitis/chronic pelvic pain syndrome(CP/CPPS) treated by thermoelectric field therapy.

Methods

From April 2018 to March 2019, 57 CP/CPPS patients treated by LR-2005 thermoelectric field therapeutic Machine. The patients were aged 20-50 years, and the course of the disease was ranged from 3 months to 7 years. Among them, 17 patients with one period of therapy, 32 patients with two period of therapy, and the rest with three. Each patient underwent clinical assessment and answered the questionnaire consisted of NIH-CPSI,PUF, VAS, QOL, SAS and SDS. Compared and analyzed the scores statistically.

Results

After treatment, the NIH-CPSI total score [(25.05±6.32) vs (19.54±6.16)], PUF symptom score [(10.86±4.41) vs (8.46±4.11)], PUF distress score [(5.35 ± 2.88) vs (4.03±2.33)], VAS score [(3.97±2.40) vs (2.03±1.85)], QOL score [(4.89±1.27) vs (3.95±1.25)], SAS score [(37.35±8.76) vs (34.00±8.14)], SDS score [(34.41±7.43) vs (32.05±4.78)] were all decreased significantly (P<0.01). The NIH-CPSI score increased in numbers of mild and moderate, while the severe decreased significantly (P<0.01). No special discomfort or adverse reactions occurred after treatment.

Conclusion

Thermoelectric field therapy can effectively alleviate inflammation and pain response, improve voiding symptoms, reduce anxiety and depression of CP/CPPS patients, and improve the quality of life. Its clinical curative effect is remarkable, and it fits the "painless, non-invasive and non-interventional" treatment model advocated by WHO. It was worth of promoting in clinical application.

Key words: Thermoelectric field therapy, CP/CPSS, Chronic, pelvic pain syndrome, Chronic, prostatitis

Honglu Ding, Jingwei Feng, Zhen Wu, Jialiang Chen, Bolong Liu, Zhijun Lin, Juncong Xie, Yuancheng Xu, Xiangfu Zhou. Application of thermoelectric field therapy in chronic prostatitis/chronic pelvic pain syndrome[J]. Chinese Journal of Endourology(Electronic Edition), 2020, 14(01): 56-60.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2020.01.014

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2020/V14/I01/56

Figures/Tables 2

References 21

[1]	Holt JD, Garrett WA, Mccurry TK, et al. Common questions about chronic prostatitis[J]. Am Fam Physician, 2016, 93(4): 290-296.
[2]	唐园，姜庆, 等. 慢性前列腺炎/慢性骨盆疼痛综合征治疗进展[J].科学咨询(科技·管理), 2016, 6(2): 71-73.
[3]	Suskind AM, Berry SH, Ewing BA.et al. The prevalence and ovedap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiologymale study[J]．J Urol, 2013, 189(1): 141-145.
[4]	郭应禄，胡礼泉. 男科学[M]. 北京:人民卫生出版社, 2005: 1488-1493.
[5]	齐旻芳，黄高翔，周雪娟.慢性非细菌性前列腺炎发病机制的研究进展[J]. 广西医科大学学报, 2017, 34(8): 1247-1249.
[6]	蓝天，王养民，陈烨, 等. 慢性前列腺炎相关危险因素的多中心联合调查研究[J]. 解放军医学杂志, 2010, 35(1): 79-82.
[7]	Giubilei G, Mondaini N, Minervini A, et al. Physical activity of men with chronic prostatitis/chronic pelvic pain syndrome not satisfied with conventional treatments. Could it represent avalid option the physical activity and male pelvic pain trial: Adouble-blind, randomized study[J]. J Urol, 2007, 177(1): 159-165.
[8]	邝世航，黄双艺，乐有为, 等. 慢性前列腺炎TGF-β1、CTGF的表达水平及其与症状指数的关系[J/CD]. 中华腔镜泌尿外科杂志(电子版), 2018, 12(2): 125-128.
[9]	邓云山. 慢性前列腺炎患者抑郁状况分析[J]. 中国性科学, 2012, 21(9): 5-8.
[10]	Mo MQ, Long LL, Xie WL, et al. Sexual dysfunctions and psychological disorders associated with type Ⅲa chronic prostatitis:a clinical survey in China[J]. Int Urol Nephrol, 2014, 46 (12): 2255-226．
[11]	李春弟，崔巍，蒋聿瑛. 慢性前列腺炎/慢性骨盆疼痛综合征的发病相关危险因素分析[J].中国现代医生, 2015, 53(13): 77-80.
[12]	Tripp DA, Nickel JC, Shoskes D, et al. A 2-year follow-up of quality of life, pain, and psychosocial factors in patients with chronic prostatitis /chronic pelvic pain syndrome and their spouses[J]. World J Urol, 2013, 31(4): 733-739．
[13]	Guan X, Zhao C, OU ZY, et al. Use of the UPOI NT phenotype system in treating Chinese patients with chronic prostatitis/chronic pelvic pain syndrome: a prospective study[J].Asian J Androl, 2015, 17(1): 120.
[14]	Shoskes DA, Nickel JC. Classification and treatment of men with chronic prostatitis/chronic pelvic pain syndrome using the uPOINT system[J].world J Urol, 2013, 31(4): 55-760.
[15]	张志超，彭靖.慢性前列腺炎/慢性盆腔疼痛综合征的新诊断/治疗模式-UPOINT系统[J]. 中华男科学杂志, 2013, 19(7): 579-582.
[16]	陈萍，张纪良，朱丽, 等. 化疗与热疗联合治疗晚期非小细胞肺癌的临床研究[J]. 现代临床医学, 2019, 45(4): 1-3.
[17]	WAN J, WU W. Hyperthermia induced HIF-1α expression of lung cancer through AKT and ERK signaling pathways[J]. J Exp Clin Cancer Res, 2016, 35(1): 119-129.
[18]	LEE H, KIM S, CHOI B H, et al. Hyperthermia improves therapeutic efficacy of doxorubicin carried by mesoporous silica nanocontainers in human lung cancer cells[J]. Int J Hyperthermia, 2011, 27(7): 698-707.
[19]	沈海兰. 慢性盆腔炎抗炎加盆腔深部热疗临床观察[J]. 中西医结合心血管病电子杂志, 2017, 5(30): 58-59.
[20]	刘行峰，张军杰, 等. 高频热疗机治疗慢性盆地疼痛综合征观察[J].河南外科杂志, 2004, 10(4): 76-77.
[21]	邓国政，吴媛，杨晓琼. 体外热电场辅以灌肠治疗溃疡性结肠炎28例[J]. 光明中医, 2014, 29(1): 132-133.

?	NIH-CPSI	PUF症状	PUF困扰	VAS	QOL	SDS	SAS
治疗前	25.05±6.32	10.86±4.41	5.35±2.88	3.97±2.40	4.89±1.27	37.35±8.76	34.41±7.43
治疗后	19.54±6.16	8.46±4.11	4.03±2.33	2.03±1.85	3.95±1.25	34.00±8.14	32.05±4.78
t值	9.076	10.118	6.674	8.784	8.471	6.491	6.833
P值	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

?	NIH-CPSI	PUF症状	PUF困扰	VAS	QOL	SDS	SAS
治疗前	25.05±6.32	10.86±4.41	5.35±2.88	3.97±2.40	4.89±1.27	37.35±8.76	34.41±7.43
治疗后	19.54±6.16	8.46±4.11	4.03±2.33	2.03±1.85	3.95±1.25	34.00±8.14	32.05±4.78
t值	9.076	10.118	6.674	8.784	8.471	6.491	6.833
P值	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

?	NIH-CPSI疼痛症状评分			NIH-CPSI总评分
?	轻	中	重	轻	中	重
治疗前	11（19.3%）	37（64.9%）	9（15.8%）	3（5.3%）	37（64.9%）	17（29.8%）
治疗后	29（50.9%）	26（45.6%）	2（3.5%）	13（22.8%）	42（73.7%）	2（3.5%）
χ²值	14.48			9.73
P值	<0.001			<0.001

?	NIH-CPSI疼痛症状评分			NIH-CPSI总评分
?	轻	中	重	轻	中	重
治疗前	11（19.3%）	37（64.9%）	9（15.8%）	3（5.3%）	37（64.9%）	17（29.8%）
治疗后	29（50.9%）	26（45.6%）	2（3.5%）	13（22.8%）	42（73.7%）	2（3.5%）
χ²值	14.48			9.73
P值	<0.001			<0.001

Please choose a citation manager

Content to export